In a filing, CRISPR Therapeutics AG revealed its Chief Executive Officer Kulkarni Samarth unloaded Company’s shares for reported $1.45 million on Mar 15 ’24. In the deal valued at $72.48 per share,20,000 shares were sold. As a result of this transaction, Kulkarni Samarth now holds 208,122 shares worth roughly $13.34 million.
Then, Prasad Raju sold 3,524 shares, generating $256,160 in total proceeds. Upon selling the shares at $72.69, the Chief Financial Officer now owns 6,476 shares.
Before that, Kulkarni Samarth sold 4,583 shares. CRISPR Therapeutics AG shares valued at $341,159 were divested by the Chief Executive Officer at a price of $74.44 per share. As a result of the transaction, Kulkarni Samarth now holds 208,122 shares, worth roughly $13.34 million.
Wolfe Research initiated its CRISPR Therapeutics AG [CRSP] rating to a Peer perform in a research note published recently. A number of analysts have revised their coverage, including TD Cowen’s analysts, who decreased its forecast for the stock in mid December from “a Market perform” to “an Underperform”. Cantor Fitzgerald also remained covering CRSP and has decreased its forecast on October 17, 2023 with a “Neutral” recommendation from previously “an Overweight” rating. Mizuho started covering the stock on September 27, 2023. It rated CRSP as “a Buy”.
Price Performance Review of CRSP
On Monday, CRISPR Therapeutics AG [NASDAQ:CRSP] saw its stock jump 1.89% to $64.09. Over the last five days, the stock has lost -6.00%. CRISPR Therapeutics AG shares have risen nearly 2.38% since the year began. Nevertheless, the stocks have risen 46.63% over the past one year. While a 52-week high of $91.10 was reached on 02/22/24, a 52-week low of $37.55 was recorded on 01/08/24. SMA at 50 days reached $73.66, while 200 days put it at $59.45. A total of 1.12 million shares were traded, compared to the trading of 1.0 million shares in the previous session.
Levels Of Support And Resistance For CRSP Stock
The 24-hour chart illustrates a support level at 63.00, which if violated will result in even more drops to 61.90. On the upside, there is a resistance level at 64.70. A further resistance level may holdings at 65.31. The Relative Strength Index (RSI) on the 14-day chart is 32.38, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -4.64, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 87.04%. Stochastics %K at 9.67% indicates the stock is a buying.
How much short interest is there in CRISPR Therapeutics AG?
A steep rise in short interest was recorded in CRISPR Therapeutics AG stocks on Mar 15, 2024, dropping by -0.15 million shares to a total of 14.72 million shares. Yahoo Finance data shows the prior-month short interest on Feb 15, 2024 was 14.87 million shares. There was a decline of -1.02%, which implies that there is a negative sentiment for the stock. In spite of short shares comprising just 18.59% of the overall stock float, the days-to-cover ratio (short ratio) fell to 6.82.
